Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc.

ABOS·NASDAQ

$2.37

+2.6%
HealthcareBiotechnology

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

At a Glance

Live Snapshot
Market Cap$143.56M
EPS-2.0000
P/E Ratio-1.05
Earnings Date08/11/2026

abos

Common Stock

Last Annual Value

6.00K

3-Year CAGR

14%

5-Year CAGR

%

10-Year CAGR

%

Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc. Competitors Analysis of Common Stock

ABOS · NASDAQ
CompanyCommon Stock
CAGR 3Y
CAGR 5Y
CAGR 10Y
6.00K
0.0%8.4%N/A 
SEER logo
Seer, Inc.
NASDAQ:SEER
1.00K
0.0%0.0%N/A
23.00
125.7%N/AN/A
9.00K
14.5%12.5%N/A
PEPG logo
PepGen Inc.
NASDAQ:PEPG
7.00K
51.8%N/AN/A
0.00
N/AN/AN/A
17.80K
14.0%-22.6%N/A
AGEN logo
Agenus Inc.
NASDAQ:AGEN
353.00K
-55.3%-32.8%-8.7%
29.00K
60.6%-30.7%27.3%
ALEC logo
Alector, Inc.
NASDAQ:ALEC
11.00K
11.2%6.6%N/A
69.00K
44.7%-20.5%-0.7%
Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc. Fair Value Envelope

ABOS · NASDAQ

Our analysis suggests that ABOS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.37, this represents a potential HIDDEN relative to our calculated worth for Acumen Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $2.37